Document is current
Any future updates will be listed below
-
Authors
Cusan, Monica https://orcid.org/0000-0003-4907-349X
Larkin, Karilyn
Nicolet, Deedra
Jurinovic, Vindi
Mrózek, Krzysztof https://orcid.org/0000-0002-1408-5063
Batcha, Aarif M. N.
Rothenberg-Thurley, Maja
Schneider, Stephanie
Sauerland, Cristina
Görlich, Dennis https://orcid.org/0000-0002-2574-9419
Krug, Utz
Berdel, Wolfgang E.
Woermann, Bernhard J. https://orcid.org/0000-0003-2273-5502
Hiddemann, Wolfgang
Braess, Jan https://orcid.org/0000-0001-6528-2078
Spiekermann, Karsten https://orcid.org/0000-0002-5139-4957
Greif, Philipp A.
Blachly, James S. https://orcid.org/0000-0002-4275-5562
Mims, Alice S. https://orcid.org/0000-0002-8971-2199
Walker, Christopher J.
Walker, Michael C.
Oakes, Christopher C.
Orwick, Shelley https://orcid.org/0000-0002-4537-1409
Carroll, Andrew J.
Blum, William G.
Powell, Bayard L.
Kolitz, Jonathan E.
Moore, Joseph O.
Mayer, Robert J.
Larson, Richard A.
Stone, Richard M. https://orcid.org/0000-0002-7526-2633
Byrd, John C.
Metzeler, Klaus H.
Herold, Tobias https://orcid.org/0000-0002-9615-9432
Eisfeld, Ann-Kathrin
- License Information
-
More Information
Article History
Received: 28 January 2025
Revised: 18 April 2025
Accepted: 12 May 2025
First Online: 19 September 2025
Competing interests
: The authors declare no competing interests.
: All methods were conducted in accordance with relevant guidelines and regulations. All study protocols were approved by the Institutional Review Boards of participating centers in accordance with the Declaration of Helsinki. All patients provided written informed consent for inclusion on the clinical trial and genetic analyses. Cancer Therapy Evaluation Program approval was obtained on September 13, 2024. Additional details are provided in the Supplementary Information.
